-+ 0.00%
-+ 0.00%
-+ 0.00%

Alterity Therapeutics Publishes Transcript of Chairman's Address to 2026 Annual General Meeting

PUBT·11/20/2026 11:04:17
Listen to the news
Alterity Therapeutics Publishes Transcript of Chairman's Address to 2026 Annual General Meeting
  • Alterity Therapeutics Chairman Julian Babarczy outlined FDA alignment on Phase 3 plans at the 2026 annual general meeting.
  • The alignment covers key trial design elements and a potential registration pathway for ATH434 in multiple system atrophy.
  • Cash totaled A$ 41.3 million at September-end, but launching the pivotal trial requires substantial funding.
  • Potential pharmaceutical partnerships and other strategic financing options remain under evaluation to fund the Phase 3 program.
  • Manufacturing reached the first ATH434 registration batch; a new US composition of matter patent extends protection to 2045.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-037790), on November 20, 2026, and is solely responsible for the information contained therein.